COMMUNIQUÉS West-GlobeNewswire

Elixir Medical Announces First Use of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Asia Pacific at Cardiac Vascular Sentral Kuala Lumpur (CVSKL), Malaysia
25/04/2025
First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea. Novel IVL technology designed to deliver calcium fragmentation for treatment [...]
Best Thermogenic Fat Burner Supplements 2025: Top Fat Burning Pills for Weight Loss From PhenQ
25/04/2025
Clinically-backed thermogenic fat burners accelerate metabolism, ignite fat loss, and curb appetite—PhenQ leads 2025’s top fat-burning supplements for men and women aiming for sustainable weight loss results. NEW YORK, [...]
TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
25/04/2025
The first a approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis, 1 , 2 , 3 , 4 , 5 guselkumab showed statistically higher rates of endoscopic [...]
Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease
25/04/2025
ORION CORPORATION PRESS RELEASE 25 APRIL 2025 at 9.00 EEST Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease Orion Corporation (“ [...]
Vistin Pharma ASA: First quarter 2025 financial results
25/04/2025
Oslo, Norway, 25 th of April 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2025. Revenue in the first quarter ended at MNOK 115 compared to MNOK 104 in Q1 2024. Sales [...]
SYNC Sunlight Loophole Under Review: Unique Metabolism Boosting Formula to Burn Belly Fat Fast
25/04/2025
Disrupting the Weight Loss Plateau: New Clock Gene Supplement ‘SYNC’ Restores Metabolic Rhythm for Natural Fat-Burning & All-Day Energy Aurora, Colorado, April 25, 2025 (GLOBE NEWSWIRE) -- If you've ever felt like [...]
Okita Nail Fungus Light Under Review: Best At-Home Toenail Fungus Cleaning Light for Onychomycosis
25/04/2025
Discover How the Okita Nail Fungus Light Uses Red & Blue LED Therapy to Help Improve Nail Clarity at Home—A Drug-Free, Pain-Free Solution for Onychomycosis Sufferers Seeking Visible Results Wanchai, Hong Kong, April [...]
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
25/04/2025
Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of the influenza virus, from an infected person to household members by 32% 1 CENTERSTONE is the first [...]
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
25/04/2025
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance [...]
Champions for Change Celebrated at 2025 Helen Keller Achievement Awards
25/04/2025
Author Andrew Leland Breaks Down Misconceptions of People with Disabilities; Business Leader Thomas Wlodkowski Recognized for Bolstering Access to Media; Mattel Lauded for Blind Barbie’s Global Impact on Positive [...]
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
25/04/2025
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
25/04/2025
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
24/04/2025
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its [...]
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
24/04/2025
VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
24/04/2025
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results [...]
Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025
24/04/2025
LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
24/04/2025
Exosome-Based ExoPTEN Targets Three High-Value Nerve Injury Indications TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “ [...]
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
24/04/2025
Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a first installment of € [...]
GENFIT : Résultats financiers annuels 2024 et point sur les activités de la Société
24/04/2025
Trésorerie et équivalents de trésorerie s’élevant à 81,8 millions d’euros au 31 décembre 2024. En outre, conclusion, en début d’année (i) d’un accord de royalty financing non dilutif d'un montant maximum de 185 millions [...]

Pages